Safety and efficacy of daily oral edaravone (FNP122) in patients with amyotrophic lateral sclerosis (ADORE): a multicentre, double-blind, phase 3, randomised controlled trial
In brief
Daily oral edaravone fails to slow ALS decline over 48 weeks
In a 302-patient trial, function declined by 12.6 points with edaravone and 13.4 with placebo on a standard ALS scale, a difference that was not statistically significant. Side effects were similar between groups, and no deaths were considered treatment-related. At the tested dose, the daily pill did not slow disease progression in this broader ALS population.
- Journal
- The Lancet. Neurology (Q1)
- Published
- 1 December 2026
- Study design
- Randomized controlled trial
- Evidence level
- Level 1, High (CEBM 1b)
- Authors
- Ruben P A van Eijk, Mónica Povedano, Philip Van Damme, Adriano Chiò, Christopher J McDermott, Ammar Al-Chalabi, et al.
- PMID
- 43051186
- DOI
- 10.1016/S1474-4422(26)00336-4
Why clinicians should know about it
- Picked for Neurology (clinical) (paper of the day, 19 November 2026): Phase III trial evaluates oral edaravone for amyotrophic lateral sclerosis
Abstract
BACKGROUND: Oxidative stress, resulting from excessive production of reactive oxygen species, is implicated in the pathogenesis of amyotrophic lateral sclerosis. Edaravone is a free-radical scavenger that has been shown to reduce functional decline over 24 weeks in a subset of patients with amyotrophic lateral sclerosis and is approved for its treatment in several countries. We investigated the safety and efficacy of edaravone (FNP122), a novel once-daily oral formulation of edaravone, in a broader population of patients with amyotrophic lateral sclerosis over a longer period. METHODS: This multicentre, double-blind, phase 3, randomised controlled trial was done in 37 hospitals in Belgium, France, Germany, Ireland, Italy, the Netherlands, Poland, Portugal, Russia, Spain, Sweden, and the UK. Eligible patients were adults aged 18-80 years, with amyotrophic lateral sclerosis, 24 months or less since symptom onset, vital capacity at least 70%, and rate of change in amyotrophic lateral sclerosis Functional Rating Scale-Revised (ALSFRS-R) score between 0·35 and 1·50 points per month (both inclusive). Eligible patients were randomly assigned 2:1 using a central web-based allocation system to oral edaravone (100 mg per day) or placebo. Participants, investigators, study staff, outcome assessors, and the sponsor remained masked to treatment allocation throughout the study. The primary endpoint was the mean difference in change from baseline in ALSFRS-R total score at week 48 between edaravone and placebo, assessed in patients who received at least one dose of study drug. This trial was registered with ClinicalTrials.gov (NCT05178810) and is complete. FINDINGS: Between Oct 18, 2021, and Nov 30, 2022, 370 individuals were screened, of whom 313 were randomly assigned to receive edaravone (n=209) or placebo (n=104). One site was found to be noncompliant with Good Clinical Practice and nine individuals from that site were excluded (three in the edaravone group and six in the placebo group). One patient in each group did not receive any treatment; thus, 302 individuals were treated and analysed (205 in the edaravone group and 97 in the placebo group). Median age at baseline was 59 years (IQR 53-68). 185 (61%) of 302 patients were male and 117 (39%) were female. 275 (91%) of 302 patients were White. At 48 weeks, least squares mean change from baseline in ALSFRS-R total score was not significantly different between the edaravone group (-12·6 points [SE 0·7]) and placebo group (-13·4 points [1·0], least squares mean difference 0·78 points; 95% CI -1·44 to 3·00, p=0·49). Edaravone was well tolerated, with no between-group difference in the incidence of treatment-emergent adverse events (180 [88%] of 205 patients in the edaravone group vs 82 [85%] of 97 patients in the placebo group). No deaths were considered related to study treatment. INTERPRETATION: Oral edaravone was well tolerated but did not significantly slow functional decline versus placebo over 48 weeks. These results do not support its use at the tested dose for modifying disease progression in the general amyotrophic lateral sclerosis population and highlight the need for the development of more effective therapeutic strategies. FUNDING: Ferrer.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.